

## Abbott: PharmaVitae Profile

Description:	<p><b>Introduction</b></p> <p>This analysis examines the historical and forecast performance for Abbott in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.</p>
	<p><b>Reasons to Purchase</b></p> <p>Benchmark Abbott's performance against key rivals in the ethical pharmaceutical sector</p> <p>See how the return of the rights to Boehringer Ingelheim's products, Mobic Micardis and Flomax, will affect the company's sales outlook</p> <p>Evaluate the consequences of Abbott's recent acquisition of the cardiovascular specialist Kos Pharmaceuticals</p>
Table Of Contents:	<p><b>TABLE OF CONTENTS</b></p> <p><b>CHAPTER 1 EXECUTIVE SUMMARY 4</b></p> <p>Key findings 4</p> <p>Historical and forecast ethical sales performance 5</p> <p>Therapeutic strategy 6</p> <p>Launch and expiry outlook 9</p> <p>Externalization, geographic and molecule type strategies 11</p> <p>Externalization strategy 12</p> <p>Geographic strategy 13</p> <p>Molecule type strategy 13</p> <p>SWOT analysis 14</p> <p>Strengths 14</p> <p>Weaknesses 16</p> <p>Opportunities 17</p> <p>Threats 18</p> <p><b>CHAPTER 2 CORPORATE HISTORY 30</b></p> <p>Key findings 30</p> <p>Background 31</p> <p>Key corporate developments 31</p>

M&A history	34
Knoll Pharmaceuticals	35
Kos Pharmaceuticals	35
M&A strategy	36
Current corporate structure	37
Pharmaceutical products	38
International	38
Diagnostic products	38
Ross Products	38
Current management team	39
<b>CHAPTER 3 HISTORICAL PERFORMANCE</b>	<b>40</b>
Key findings	40
Introduction	41
Revenue and growth rate analysis, 2002–05	41
Revenue and growth rate vs. peer set	42
Product analysis, 2002–05	44
Growth drivers	44
Growth resistors	47
Operating revenue and cost analysis, 2002–05	48
Operating revenue/cost analysis	51
<b>CHAPTER 4 FORECAST PERFORMANCE</b>	<b>54</b>
Key findings	54
Introduction	55
Revenue and growth rate, 2005–11	55
Product analysis, 2005–11	57
Growth drivers	63
Growth resistors	65
Therapy area analysis, 2005–11	70
Growth drivers	74
Growth resistors	74
Other	76
Therapy area focus	77
Launches and expiries analysis, 2005–11	81
Launch portfolio	82
Core portfolio	85
Expiry portfolio	88
Launch/core/expiry configuration	91
Externalization analysis, 2005–11	94

Geographic analysis, 2005–11	100
Molecule type analysis, 2005–11	103
<b>CHAPTER 5 KEY PRODUCTS AND COMPETITORS</b>	<b>108</b>
Key findings	108
Overview	109
AIID	110
Humira	110
ABT-874	117
CNS	121
Depakote	121
Sevorane	126
Dilaudid	130
Vicodin CR	134
Infectious disease	137
Kaletra	137
Biaxin	143
Numax	148
Omnicef	154
Gastrointestinal	159
Prevacid	159
Diabetes and endocrinology	165
Zemplar	165
Cardiovascular	170
Cardiovascular	170
TriCor	170
Oncology	176
Oncology	176
Lupron	176
R&D pipeline	181
R&D pipeline	181
<b>CHAPTER 6 APPENDIX</b>	<b>183</b>
IMS vs. company-reported data reconciliation	183
References	185
Abbreviations	186
<b>TABLE OF TABLES</b>	
Table 1: Abbott Corporate Executive Committee	39
Table 2: Peer set overview	42

Table 3: Operating revenue/cost analysis (\$m), 2002–05	48
Table 4: Operating cost ratio analysis (% of total revenues), 2002–05	51
Table 5: Product portfolio overview, sales (\$m), 2005–11	57
Table 6: Therapy area overview, sales (\$m), 2005–11	70
Table 7: Launch portfolio overview, sales (\$m), 2005–11	82
Table 8: Core portfolio overview, sales (\$m), 2005–11	85
Table 9: Expiry portfolio overview, sales (\$m), 2005–11	88
Table 10: Externally developed portfolio, 2005–11 (\$m)	94
Table 11: Molecule type overview, sales (\$m), 2005–11	103
Table 12: Key products overview	109
Table 13: Humira: overview	110
Table 14: Humira: sales forecast (\$m), 2005–11	111
Table 15: Humira: newsflow	111
Table 16: ABT-874: overview	117
Table 17: ABT-874: sales forecast (\$m), 2005–11	118
Table 18: ABT-874: newsflow	118
Table 19: Depakote: overview	121
Table 20: Depakote: sales forecast (\$m), 2005–11	122
Table 21: Depakote: newsflow	122
Table 22: Sevorane: overview	126
Table 23: Sevorane: sales forecast (\$m), 2005–11	127
Table 24: Sevorane: newsflow	127
Table 25: Dilaudid: overview	130
Table 26: Dilaudid: sales forecast (\$m), 2005–11	131
Table 27: Dilaudid: newsflow	131
Table 28: Vicodin CR: overview	134
Table 29: Vicodin CR: sales forecast (\$m), 2005–11	135
Table 30: Vicodin CR: newsflow	135
Table 31: Kaletra: overview	137
Table 32: Kaletra: sales forecast (\$m), 2005–11	138
Table 33: Kaletra: newsflow	138
Table 34: Biaxin: overview	143
Table 35: Biaxin: sales forecast (\$m), 2005–11	144
Table 36: Biaxin: newsflow	144
Table 37: Numax: overview	148
Table 38: Numax: sales forecast (\$m), 2005–11	149
Table 39: Numax: newsflow	150
Table 40: Omnicef: overview	154

Table 41: Omnicef: sales forecast (\$m), 2005–11	155
Table 42: Omnicef: newsflow	155
Table 43: Prevacid: overview	159
Table 44: Prevacid: sales forecast (\$m), 2005–11	160
Table 45: Prevacid: newsflow	161
Table 46: Zemplar: overview	165
Table 47: Zemplar: sales forecast (\$m), 2005–11	166
Table 48: Zemplar: newsflow	167
Table 49: TriCor: overview	170
Table 50: TriCor: sales forecast (\$m), 2005–11	171
Table 51: TriCor: newsflow	172
Table 52: Lupron: overview	176
Table 53: Lupron: sales forecast (\$m), 2005–11	177
Table 54: Lupron: newsflow	178
Table 55: Abbott's R&D pipeline (Phase I–registration)	181
Table 56: Abbott's indication broadening pipeline (Phase I–registration)	182

#### TABLE OF FIGURES

Figure 1: Historical and forecast ethical sales performance (% CAGR), Abbott and Big Pharma peer set	5
Figure 2: Therapeutic focus vs. Big Pharma peer set (%)	2005 7
Figure 3: Launch, core and expiry, absolute sales growth, 2005–11 (sales as % of 2005 sales), Abbott	9
Figure 4: Launch, core and expiry, absolute sales growth, 2005–11 (sales as % of 2005 sales), peer set	10
Figure 5: Molecule type, externalization and geographic market dependency (%) vs. peer set, 2005	11
Figure 6: Molecule type, externalization and geographic market dependency (%) vs. peer set, 2011	12
Figure 7: SWOT analysis of Abbott	14
Figure 8: M&A/divestment history	34
Figure 9: Current corporate structure	37
Figure 10: Revenue & growth rate (ethical sales) (\$m), 2002–05	41
Figure 11: Ethical revenue (\$m) and growth rate (%) vs. peer set, 2002–05	43
Figure 12: Growth drivers/resistor products of historical revenue performance (\$m), 2002–05	44
Figure 13: Operating revenue/cost analysis (\$m), 2002–05	50
Figure 14: Operating cost ratio analysis (% of total revenues), 2002–05	52
Figure 15: Operating cost ratio vs. peer set, 2002–05	53
Figure 16: Ethical revenue (\$m) and growth rate (%), 2005–11	55
Figure 17: Top five products by sales (\$m), 2005	59
Figure 18: Top five products by sales (\$m), 2011	61
Figure 19: Growth drivers and resistors by product, 2005–11	63

- Figure 20: Key strategic products, sales (\$m), 2005–11 69
- Figure 21: Ethical sales by therapy area (\$m), 2005–11 71
- Figure 22: Growth drivers and resistors by therapy area (%), 2005–11 73
- Figure 23: Ethical sales by therapy area (%), 2005–11 77
- Figure 24: Therapy area focus compared with peer set (% total ethical sales), 2005 78
- Figure 25: Therapy area focus compared with peer set (% total ethical sales), 2011 80
- Figure 26: Launch schedule, sales (\$m), 2005–11 84
- Figure 27: Core products sales growth (\$m), 2005–11 87
- Figure 28: Expiry schedule, sales (\$m), 2005–11 90
- Figure 29: Launch, core and expiry, sales (\$m), 2005–11 91
- Figure 30: Launch, core and expiry, absolute sales growth, 2005–11 (sales as % of 2005 sales), Abbott 92
- Figure 31: Launch, core and expiry, absolute sales growth, 2005–11 (sales as % of 2005 sales), peer set 93
- Figure 32: Externalization dependency, sales (\$m), 2005–11 96
- Figure 33: Growth drivers and resistors, externally vs. internally discovered products, sales (\$m), 2005–11 97
- Figure 34: Externalization dependency vs. peer set, % total sales, 2005 98
- Figure 35: Externalization dependency vs. peer set, % total sales, 2011 99
- Figure 36: Geographical sales breakdown (\$m), 2005–11 100
- Figure 37: Growth drivers and resistors by geography, sales (\$m), 2005–11 101
- Figure 38: US dependency vs. peer set, % total sales, 2005 102
- Figure 39: US dependency vs. peer set, % total sales, 2011 103
- Figure 40: Growth drivers and resistors by molecule type, sales (\$m), 2005–11 104
- Figure 41: Molecule type sales breakdown (\$m), 2005–11 105
- Figure 42: Biologics dependency vs. peer set, % total sales, 2005 106
- Figure 43: Biologics dependency vs. peer set, % total sales, 2011 107
- Figure 44: IMS vs. company-reported ethical sales discrepancy (\$m), 2005 184
- Figure 45: IMS vs. company-reported ethical sales forecast growth rates (%), 2005–11 185